Spots Global Cancer Trial Database for Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases

Official Title: A Phase II Trial of Hepatic Artery Infusional Floxuridine With Systemic Chemotherapy in the Treatment of Pancreatic Cancer Liver Metastases

Study ID: NCT03856658

Conditions

Pancreatic Adenocarcinoma

Liver Metastases

Interventions

Floxuridine (FUDR)

Hepatic Artery Infusion Pump

Heparinized Saline

Study Description

Brief Summary: This is a single arm, phase II study without blinding. The purpose is to determine the impact of hepatic artery infusion Floxuridine (FUDR) on liver metastases from pancreatic adenocarcinoma. Patients at Spectrum Health will receive standard of care chemotherapy. They will also receive chemotherapy via surgically placed hepatic artery infusion (HAI) pump.

Detailed Description: This study hypothesizes that the combination of Floxuridine (FUDR), a type of chemotherapy, delivered via a hepatic artery infusion (HAI) pump, with standard of care systemic chemotherapy will lead to improved survival in the treatment of pancreatic cancer liver metastases. Patients will receive 6 cycles of FUDR and will be followed for two years.